CN Patent

CN114728899B — 新型三苯基化合物盐

Assigned to Taiho Pharmaceutical Co Ltd · Expires 2023-12-05 · 2y expired

What this patent protects

本发明提供4‑[5‑[(3S)‑3‑氨基吡咯烷‑1‑羰基]‑2‑[2‑氟‑4‑(2‑羟基‑2‑甲基‑丙基)苯基]苯基]‑2‑氟‑苯甲腈的苯甲酸盐。还提供4‑[5‑[(3S)‑3‑氨基吡咯烷‑1‑羰基]‑2‑[2‑氟‑4‑(2‑羟基‑2‑甲基‑丙基)苯基]苯基]‑2‑氟‑苯甲腈的山梨酸盐。

USPTO Abstract

本发明提供4‑[5‑[(3S)‑3‑氨基吡咯烷‑1‑羰基]‑2‑[2‑氟‑4‑(2‑羟基‑2‑甲基‑丙基)苯基]苯基]‑2‑氟‑苯甲腈的苯甲酸盐。还提供4‑[5‑[(3S)‑3‑氨基吡咯烷‑1‑羰基]‑2‑[2‑氟‑4‑(2‑羟基‑2‑甲基‑丙基)苯基]苯基]‑2‑氟‑苯甲腈的山梨酸盐。

Drugs covered by this patent

Patent Metadata

Patent number
CN114728899B
Jurisdiction
CN
Classification
—
Expires
2023-12-05
Drug substance claim
No
Drug product claim
No
Assignee
Taiho Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.